Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 11Colorectal Neoplasms 10Neoplasm Metastasis 6Rhabdomyosarcoma 3Neuroblastoma 3Lung Neoplasms 3Cholangiocarcinoma 3Biliary Tract Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Sarcoma 2Rectal Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Neuroendocrine 2Uterine Cervical Neoplasms 1Solid Tumors 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Refractory Solid Tumors 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Medulloblastoma 1Malignant mesenchymal tumor 1Intestinal Neoplasms 1Gastrointestinal Neoplasms 1

Interventions

Bevacizumab 3repotrectinib 1durvalumab 1atezolizumab 1Tretinoin 1Oviposition 1Leucovorin 1Irinotecan 1Immunotherapy 1Imatinib Mesylate 1Fluorouracil 1Drug Therapy 1Drainage 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Digestive System Neoplasms × Irinotecan × 30 days × Clear all
NCT03303495 2026-06-05

A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

Sun Yat-sen University

Phase 3 Recruiting
280 enrolled
Gastrointestinal

Digestive System Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡